AIM ImmunoTech Inc. SEC filings AIM
AIM ImmunoTech Inc. has 1,001 filings in SEC EDGAR's recent list, going back to Dec 6, 2013. Its latest annual report, Form ARS, was filed on Sep 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 7, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Jun 23, 2026 | — |
| CORRESP | Letter to the SEC | Jun 18, 2026 | — |
| UPLOAD | Letter from the SEC | Jun 18, 2026 | — |
| EFFECT | Filing | Jun 16, 2026 | — |
| CORRESP | Letter to the SEC | Jun 15, 2026 | — |
| UPLOAD | Letter from the SEC | Jun 12, 2026 | — |
| EFFECT | Filing | Feb 10, 2026 | — |
| CORRESP | Letter to the SEC | Feb 6, 2026 | — |
| CORRESP | Letter to the SEC | Jan 29, 2026 | — |
| CORRESP | Letter to the SEC | Jan 23, 2026 | — |
| NT 10-Q | Filing | Nov 17, 2025 | Sep 30, 2025 |
| EFFECT | Filing | Jul 28, 2025 | — |
| CORRESP | Letter to the SEC | Jul 24, 2025 | — |
| CORRESP | Letter to the SEC | Jul 24, 2025 | — |
| CORRESP | Letter to the SEC | Jul 15, 2025 | — |
| EFFECT | Filing | Jul 3, 2025 | — |
| CORRESP | Letter to the SEC | Jun 30, 2025 | — |
| CORRESP | Letter to the SEC | Jun 27, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 3, 2025 | — |
| CORRESP | Letter to the SEC | Feb 13, 2025 | — |
| CORRESP | Letter to the SEC | Feb 6, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 29, 2025 | — |
| CORRESP | Letter to the SEC | Jan 23, 2025 | — |
| DFAN14A | Filing | Dec 16, 2024 | — |
| DFAN14A | Filing | Dec 13, 2024 | — |
| DFAN14A | Filing | Dec 12, 2024 | — |
| DFAN14A | Filing | Dec 12, 2024 | — |
| DFAN14A | Filing | Dec 11, 2024 | — |
| DFAN14A | Filing | Dec 10, 2024 | — |
| DFAN14A | Filing | Dec 10, 2024 | — |
| DFAN14A | Filing | Dec 6, 2024 | — |
| EFFECT | Filing | Dec 4, 2024 | — |
| DFAN14A | Filing | Dec 2, 2024 | — |
| DFAN14A | Filing | Nov 27, 2024 | — |
| CORRESP | Letter to the SEC | Nov 26, 2024 | — |
| DFAN14A | Filing | Nov 26, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 21, 2024 | — |
| DFAN14A | Filing | Nov 20, 2024 | — |
| DFAN14A | Filing | Nov 19, 2024 | — |
| CORRESP | Letter to the SEC | Nov 15, 2024 | — |
| DFAN14A | Filing | Nov 14, 2024 | — |
| DEFC14A | Filing | Nov 6, 2024 | — |
| DEFC14A | Filing | Nov 4, 2024 | — |
| CORRESP | Letter to the SEC | Oct 30, 2024 | — |
| PRER14A | Filing | Oct 30, 2024 | — |
| PRRN14A | Filing | Oct 30, 2024 | — |
| UPLOAD | Letter from the SEC | Oct 28, 2024 | — |
| UPLOAD | Letter from the SEC | Oct 28, 2024 | — |
| PREC14A | Filing | Oct 18, 2024 | — |
| PREC14A | Filing | Oct 15, 2024 | — |
| EFFECT | Filing | Jul 25, 2024 | — |
| CORRESP | Letter to the SEC | Jul 22, 2024 | — |
| CORRESP | Letter to the SEC | Jul 19, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 16, 2024 | — |
| CORRESP | Letter to the SEC | Jul 11, 2024 | — |
| EFFECT | Filing | May 1, 2024 | — |
| CORRESP | Letter to the SEC | Apr 25, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 25, 2024 | — |
| CORRESP | Letter to the SEC | Apr 19, 2024 | — |
| D/A | Filing | Feb 21, 2024 | — |
| D | Filing | Feb 20, 2024 | — |
| DFAN14A | Filing | Jan 3, 2024 | — |
| DFAN14A | Filing | Nov 20, 2023 | — |
| DFAN14A | Filing | Nov 16, 2023 | — |
| DEFC14A | Filing | Nov 6, 2023 | — |
| DEFC14A | Filing | Nov 1, 2023 | — |
| CORRESP | Letter to the SEC | Oct 24, 2023 | — |
| PRER14A | Filing | Oct 24, 2023 | — |
| UPLOAD | Letter from the SEC | Oct 20, 2023 | — |
| UPLOAD | Letter from the SEC | Oct 19, 2023 | — |
| PREC14A | Filing | Oct 13, 2023 | — |
| PREC14A | Filing | Oct 10, 2023 | — |
| DFAN14A | Filing | Aug 28, 2023 | — |
| 8-A12B/A | Filing | May 12, 2023 | — |
| 8-A12B/A | Filing | Feb 10, 2023 | — |
| 8-A12B/A | Filing | Nov 14, 2022 | — |
| DFAN14A | Filing | Nov 2, 2022 | — |
| DFAN14A | Filing | Oct 24, 2022 | — |
| DFAN14A | Filing | Oct 19, 2022 | — |
| DFAN14A | Filing | Oct 13, 2022 | — |
| DFAN14A | Filing | Sep 28, 2022 | — |
| DEFC14A | Filing | Sep 28, 2022 | — |
| UPLOAD | Letter from the SEC | Sep 26, 2022 | — |
| PRRN14A | Filing | Sep 23, 2022 | — |
| UPLOAD | Letter from the SEC | Sep 22, 2022 | — |
| CORRESP | Letter to the SEC | Sep 21, 2022 | — |
| DEFR14A | Filing | Sep 21, 2022 | — |
| UPLOAD | Letter from the SEC | Sep 20, 2022 | — |
| DEFC14A | Filing | Sep 19, 2022 | — |
| PREC14A | Filing | Sep 15, 2022 | — |
| PREC14A | Filing | Sep 9, 2022 | — |
| DFAN14A | Filing | Aug 16, 2022 | — |
| DFAN14A | Filing | Jul 21, 2022 | — |
| EFFECT | Filing | Feb 4, 2022 | — |
| CORRESP | Letter to the SEC | Jan 31, 2022 | — |
| UPLOAD | Letter from the SEC | Jan 26, 2022 | — |
| EFFECT | Filing | Jan 21, 2022 | — |
| UPLOAD | Letter from the SEC | Sep 26, 2019 | — |
| EFFECT | Filing | Sep 25, 2019 | — |
| UPLOAD | Letter from the SEC | Sep 24, 2019 | — |
| CORRESP | Letter to the SEC | Sep 24, 2019 | — |
| CORRESP | Letter to the SEC | Sep 24, 2019 | — |
| CORRESP | Letter to the SEC | Sep 24, 2019 | — |
| UPLOAD | Letter from the SEC | Sep 12, 2019 | — |
| CORRESP | Letter to the SEC | Sep 6, 2019 | — |
| EFFECT | Filing | Feb 14, 2019 | — |
| CORRESP | Letter to the SEC | Feb 11, 2019 | — |
| CORRESP | Letter to the SEC | Feb 6, 2019 | — |
| EFFECT | Filing | Aug 3, 2018 | — |
| EFFECT | Filing | Aug 3, 2018 | — |
| CORRESP | Letter to the SEC | Jul 31, 2018 | — |
| CORRESP | Letter to the SEC | Jul 31, 2018 | — |
| CORRESP | Letter to the SEC | Jul 20, 2018 | — |
| CORRESP | Letter to the SEC | Jul 20, 2018 | — |
| UPLOAD | Letter from the SEC | Jul 11, 2018 | — |
| UPLOAD | Letter from the SEC | Jul 11, 2018 | — |
| D | Filing | Apr 25, 2018 | — |
| CERTNYS | Auto-generated paper document | Nov 16, 2017 | — |
| 8-A12B | Filing | Nov 14, 2017 | — |
| EFFECT | Filing | Oct 12, 2017 | — |
| UPLOAD | Letter from the SEC | Oct 11, 2017 | — |
| CORRESP | Letter to the SEC | Oct 10, 2017 | — |
| EFFECT | Filing | May 23, 2017 | — |
| CORRESP | Letter to the SEC | May 19, 2017 | — |
| CORRESP | Letter to the SEC | May 19, 2017 | — |
| CT ORDER | Filing | May 16, 2017 | — |
| UPLOAD | Letter from the SEC | May 15, 2017 | — |
| CORRESP | Letter to the SEC | May 4, 2017 | — |
| D | Filing | Feb 13, 2017 | — |
| CT ORDER | Filing | Oct 11, 2016 | — |
| CT ORDER | Filing | Sep 19, 2016 | — |
| D | Filing | Sep 2, 2016 | — |
| PRER14A | Filing | Jun 9, 2016 | — |
| CT ORDER | Filing | Mar 11, 2016 | — |
| CT ORDER | Filing | Jan 8, 2016 | — |
| EFFECT | Filing | Aug 4, 2015 | — |
| CORRESP | Letter to the SEC | Aug 3, 2015 | — |
| UPLOAD | Letter from the SEC | Jul 2, 2015 | — |
| CT ORDER | Filing | Jul 2, 2015 | — |
Showing 139 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- AIM (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Ocala, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 946644
- Former names
- AIM ImmunoTech Inc. (until Nov 5, 2026); HEMISPHERX BIOPHARMA INC (until Aug 26, 2019)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.